先健科技(1302.HK)漲超7% 高瓴6億入股且子公司元心科技引入1.6億戰投
格隆匯11月26日丨先健科技(1302.HK)今日明顯走強,一度漲7.07%報3.18港元,市值137億港元。據港交所披露,高瓴於11月20日買入2.62478億股先健科技(1302.HK),平均代價為2.3港元/股,涉資約6億港元,買入後高瓴持股數佔先健科技總股本的比例為6.06%。此外,先健科技控股子公司元心科技順利引入了包括IDG資本、基石投資在內的多家戰略投資者,引入資金1.6億。格隆匯平台近日推出“2021 Tenbagger系列之先健科技”,已先後推出兩篇深度文章《集採下的思索與機會》《第二批集採來臨,何去何從?》,對先健科技的最新動態及背後的投資邏輯進行了深度解讀,詳情可點擊下列鏈接。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.